肺纤维化合并肺气肿(Combined Pulmonary Fibrosis with Emphysema,CPFE)综合征是指肺部同时发生两种疾病过程,难以诊断,但存在高发病率和死亡率。CPFE的诊断具有挑战性,因为这两种疾病可以抵消各自的损害,导致CPFE患者的胸部X线检查和...肺纤维化合并肺气肿(Combined Pulmonary Fibrosis with Emphysema,CPFE)综合征是指肺部同时发生两种疾病过程,难以诊断,但存在高发病率和死亡率。CPFE的诊断具有挑战性,因为这两种疾病可以抵消各自的损害,导致CPFE患者的胸部X线检查和肺功能测定看似正常。2005年,Cottin首次将此命名为CPFE,其特征是劳累性呼吸困难,胸部高分辨CT(HRCT)表现为上叶肺气肿和下叶肺纤维化,肺容量相对正常和一氧化碳弥散量(Diffusion capacity of the lung for carbon monoxide,D_(L)CO)严重降低,它在世界范围内的患病率各不相同,男性占主导地位,吸烟史超过40包/年是一个常见的风险因素。CPFE常并发肺动脉高压,急性肺损伤和肺癌,预后较差,然而CPFE尚未引起临床医生的广泛关注,本文旨在提高人们对CPFE的认识,并在临床实践中探索新的有效治疗策略。展开更多
慢性阻塞性肺病(COPD)是一种常见的异质性呼吸道疾病,其特征是持续性和不完全可逆的气流受限。由于COPD的异质性和表型复杂性,传统的诊断方法只能提供有限的预测结果和治疗信息,不足以进行准确的诊断和评估。随着近年来组学技术的发展,...慢性阻塞性肺病(COPD)是一种常见的异质性呼吸道疾病,其特征是持续性和不完全可逆的气流受限。由于COPD的异质性和表型复杂性,传统的诊断方法只能提供有限的预测结果和治疗信息,不足以进行准确的诊断和评估。随着近年来组学技术的发展,基因组学、蛋白质组学和代谢组学被广泛应用于COPD的研究,为发现生物标志物以诊断和阐明COPD的复杂机制提供了良好的工具。在这篇综述中,我们基于近年来报道的代谢组学、蛋白质组学和转录组学研究,总结了COPD不同的代谢途径、生物标志物、潜在治疗靶点、代谢组学的手段,蛋白标志物,部分基因,以解释COPD的发病机制。最后,提出了COPD研究的前景和挑战。期望这篇综述将为COPD诊断方法的发展和发病机制的阐明提供一些参考。Chronic obstructive pulmonary disease (COPD) is a common heterogeneous respiratory disease characterized by persistent and incompletely reversible airflow restriction. Due to the heterogene-ity and phenotypic complexity of COPD, traditional diagnostic methods can only provide limited predictive results and treatment information, which is insufficient for accurate diagnosis and eval-uation. With the development of omics technology in recent years, Genomics, Proteomics and metabonomics have been widely used in the study of COPD, providing a good tool for discovering biomarkers to diagnose and clarify the complex mechanism of COPD. In this review, based on metabonomics, Proteomics and Transcriptome studies reported in recent years, we summarized the different metabolic pathways, biomarkers, potential therapeutic targets, metabonomics means, protein markers, and some genes of COPD to explain the pathogenesis of COPD. Finally, the pro-spects and challenges of COPD research were proposed. It is expected that this review will provide some reference for the development of diagnostic methods and elucidation of the pathogenesis of COPD.展开更多
文摘肺纤维化合并肺气肿(Combined Pulmonary Fibrosis with Emphysema,CPFE)综合征是指肺部同时发生两种疾病过程,难以诊断,但存在高发病率和死亡率。CPFE的诊断具有挑战性,因为这两种疾病可以抵消各自的损害,导致CPFE患者的胸部X线检查和肺功能测定看似正常。2005年,Cottin首次将此命名为CPFE,其特征是劳累性呼吸困难,胸部高分辨CT(HRCT)表现为上叶肺气肿和下叶肺纤维化,肺容量相对正常和一氧化碳弥散量(Diffusion capacity of the lung for carbon monoxide,D_(L)CO)严重降低,它在世界范围内的患病率各不相同,男性占主导地位,吸烟史超过40包/年是一个常见的风险因素。CPFE常并发肺动脉高压,急性肺损伤和肺癌,预后较差,然而CPFE尚未引起临床医生的广泛关注,本文旨在提高人们对CPFE的认识,并在临床实践中探索新的有效治疗策略。
文摘慢性阻塞性肺病(COPD)是一种常见的异质性呼吸道疾病,其特征是持续性和不完全可逆的气流受限。由于COPD的异质性和表型复杂性,传统的诊断方法只能提供有限的预测结果和治疗信息,不足以进行准确的诊断和评估。随着近年来组学技术的发展,基因组学、蛋白质组学和代谢组学被广泛应用于COPD的研究,为发现生物标志物以诊断和阐明COPD的复杂机制提供了良好的工具。在这篇综述中,我们基于近年来报道的代谢组学、蛋白质组学和转录组学研究,总结了COPD不同的代谢途径、生物标志物、潜在治疗靶点、代谢组学的手段,蛋白标志物,部分基因,以解释COPD的发病机制。最后,提出了COPD研究的前景和挑战。期望这篇综述将为COPD诊断方法的发展和发病机制的阐明提供一些参考。Chronic obstructive pulmonary disease (COPD) is a common heterogeneous respiratory disease characterized by persistent and incompletely reversible airflow restriction. Due to the heterogene-ity and phenotypic complexity of COPD, traditional diagnostic methods can only provide limited predictive results and treatment information, which is insufficient for accurate diagnosis and eval-uation. With the development of omics technology in recent years, Genomics, Proteomics and metabonomics have been widely used in the study of COPD, providing a good tool for discovering biomarkers to diagnose and clarify the complex mechanism of COPD. In this review, based on metabonomics, Proteomics and Transcriptome studies reported in recent years, we summarized the different metabolic pathways, biomarkers, potential therapeutic targets, metabonomics means, protein markers, and some genes of COPD to explain the pathogenesis of COPD. Finally, the pro-spects and challenges of COPD research were proposed. It is expected that this review will provide some reference for the development of diagnostic methods and elucidation of the pathogenesis of COPD.
